Ro60-0175

From Self-sufficiency
Jump to: navigation, search
Ro60-0175
240px
Systematic (IUPAC) name
(S)-6-Chloro-5-fluoro-1H-indole-2-propanamine
Identifiers
CAS Number 169675-09-6
PubChem CID 5312145
Chemical data
Formula C11H12ClFN2
Molar mass 226.677 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ro60-0175 is a drug developed by Hoffmann–La Roche, which has applications in scientific research.[1][2] It acts as a potent and selective agonist for both the 5-HT2B and 5-HT2C serotonin receptor subtypes, with good selectivity over the closely related 5-HT2A subtype, and little or no affinity at other receptors.[3][4]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Quarta D, Naylor CG, Stolerman IP. The serotonin 2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology (Berlin). 2007 Aug;193(3):391-402. PMID 17473916
  2. Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA. The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology. 2008 May;33(6):1402-12. PMID 17653111
  3. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. British Journal of Pharmacology. 1999 Sep;128(1):13-20. PMID 10498829
  4. Damjanoska KJ, Muma NA, Zhang Y, D'Souza DN, Garcia F, Carrasco GA, Kindel GH, Haskins KA, Shankaran M, Petersen BR, Van De Kar LD. Neuroendocrine evidence that (S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. Journal of Pharmacology and Experimental Therapeutics. 2003 Mar;304(3):1209-16. PMID 12604698